KENINGFORD PARTNERS

CAPITAL ADVISORY

SECTOR PRIMER · TECHNOLOGY & LIFE SCIENCES

Healthcare AI Equity Trajectory: 2026 Sector Review

How growth-stage healthcare AI companies are positioning for institutional capital — reimbursement clarity, clinical validation, and enterprise distribution as the new underwriting baseline.

JUNE 2026 · KENINGFORD PARTNERS RESEARCH

keningfordpartners.com

Healthcare AI financing in 2026 rewards companies that can be underwritten as durable healthcare businesses — not experimental technology projects. This review examines how growth-stage healthcare AI companies are accessing institutional capital, where multiples have held, and where processes have stalled.

SECTION 01 OF 06

Market Context

Healthcare AI sits at the intersection of enterprise software capital flows and healthcare services underwriting standards. Investors with software mandates and investors with healthcare mandates are both active, but they converge only on assets that satisfy both lenses: recurring or contracted revenue, measurable clinical or economic outcomes, and a distribution path that does not depend on a single pilot customer.

SECTION 02 OF 06

Valuation Dispersion

Valuation outcomes in 2025 and early 2026 were bifurcated. Assets with provider-system embedding, multi-site deployment, and revenue tied to workflow adoption cleared at premium multiples relative to horizontal software peers. Assets without reimbursement clarity, with concentrated customer bases, or with pilots that had not converted to contracts faced longer processes and more structured terms.

SECTION 03 OF 06

Diligence Priorities

Investment committees moved reimbursement pathway analysis, payer mix disclosure, and clinical validation timelines into first-round diligence. Customer reference quality — particularly from health-system economic buyers — carried more weight than model performance metrics alone.

SECTION 04 OF 06

Structure Trends

Structured equity, milestone-linked tranches, and insider-led extensions appeared more frequently for pre-commercial assets. For assets with visible ARR, straight preferred rounds remained available to companies with clean retention and capital efficiency metrics.

SECTION 05 OF 06

Preparation Checklist

Companies preparing a 2026 raise should separate R&D from commercial spend in the financial model, document outcomes by cohort, and prepare payer and provider references before launch. Materials that treat clinical credibility and unit economics as one narrative consistently outperformed technology-only stories.

SECTION 06 OF 06

Methodology

Compiled from sector mandates, investor conversations, and public market comparables as of Q2 2026. For informational purposes only.

NEXT STEP

Discuss this with our team

Keningford Partners is a New York-based, principal-led capital advisory and M&A firm advising companies from Series A through the pre-IPO stage, alongside institutional investors, on equity, debt, and strategic transactions. Every mandate is led directly by senior bankers from origination through close.

EMAIL

info@keningfordpartners.com

PHONE

+1 (315) 932-6269

OFFICE

136 Madison Ave, 7th Floor, New York, NY 10016, USA

WEB

keningfordpartners.com